Related Experiment Video
Updated: Jun 12, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Imatinib decreases endometrial stromal cell transmesothial migration and proliferation in the extracellular matrix of
Jason S Griffith1, Peter A Binkley, Namir B Kirma
1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Texas Health Science Center San Antonio, San Antonio, Texas, USA. jgriffith@hfi-ivf.com
Objective:
To characterize imatinib's effect on endometrial stromal cell (ESC) attachment, proliferation, and invasion in modeled peritoneum.
Design:
In vitro study.
Setting:
Academic medical center.
Patient(S):
Twelve normally cycling women.
Intervention(S):
Imatinib treatment in ESCs from women without endometriosis.
Main Outcome Measure(S):
Rate of ESC attachment, proliferation, and invasion.
Result(S):
Imatinib treatment at 10 μM had no effect on ESC attachment. Treatment with 0.5 μM, 2 μM, and 10 μM of imatinib reduced ESC proliferation by 30%, 72%, and 76%, respectively. The 0.1 μM dose of imatinib had no effect on proliferation. Treatment with 5 μM and 10 μM of imatinib reduced ESC invasion by 30% and 73%, respectively. The 2 μM dose had no effect on invasion.
Conclusion(S):
Imatinib treatment reduces ESC proliferation and invasion in modeled peritoneum without altering attachment. Imatinib may have a therapeutic role in endometriosis treatment.
